Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry

Conclusions No differences in DAS28-remission were found between the study drugs and adalimumab as first biologic in patients with RA, independently of the BMI cohort. We did not find evidence that treatment with abatacept increased the likelihood of remission compared with adalimumab among obese patients with RA.

http://bmjopen.bmj.com/cgi/content/short/14/2/e074864?rss=1

Source: BMJ Open - February 8, 2024 Category: General Medicine Authors: Vallejo-Yagüe, E., Burkard, T., Finckh, A., Burden, A. M., On behalf of the clinicians and patients of the Swiss Clinical Quality Management Program Tags: Open access, Rheumatology Source Type: research